WEST LAFAYETTE, Ind.
Biopharmaceutical company Endocyte Inc. said Tuesday it has filed for an initial public offering.
The company said the number of shares to be offered and their price range have yet to be determined.
RBC Capital Markets and Leerink Swann LLC will act as joint book-running managers of the proposed offering. Wedbush PacGrow Life Sciences and Baird will be co-managing the offering.
Endocyte develops therapies to treat cancer and inflammatory diseases using technology to create small molecule drug conjugates and companion-imaging diagnostics that target receptors on diseased cells.